The response was messy and immediate. Enthusiasts cheered: improved reconstructions of neuron cultures, clearer views of bacterial biofilms, tiny mechanical features rendered for designers of microscopic robotics. Others pushed back: venture funds sent lawyers; a defense contractor prodded for private access. A small team from a hospital offered ethically reviewed clinical datasets and asked permission to use the pipeline for a rare-disease study. The stewards convened a review and, after careful deliberation and added safeguards, they allowed it with oversight.